Traws Pharma, Inc.

DB:0T20 주식 보고서

시가총액: €13.8m

Traws Pharma 미래 성장

Future 기준 확인 0/6

Traws Pharma is forecast to grow revenue at 1% per annum. EPS is expected to grow by 76.3% per annum.

주요 정보

n/a

수익 성장률

76.3%

EPS 성장률

Pharmaceuticals 수익 성장18.0%
매출 성장률1.0%
향후 자기자본 수익률n/a
애널리스트 커버리지

Low

마지막 업데이트09 Oct 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:0T20 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20250N/AN/AN/A1
12/31/20240N/AN/AN/A1
6/30/20240-137-23-23N/A
3/31/20240-18-18-18N/A
12/31/20230-19-18-18N/A
9/30/20230-20-17-17N/A
6/30/20230-21-17-17N/A
3/31/20230-21-17-17N/A
12/31/20220-19-16-16N/A
9/30/20220-17-17-17N/A
6/30/20220-15-17-17N/A
3/31/20220-16-17-17N/A
12/31/20210-16-19-19N/A
9/30/20210-19-21-21N/A
6/30/20210-22-22-22N/A
3/31/20210-25-23-23N/A
12/31/20200-25-23-23N/A
9/30/20200-24-23-23N/A
6/30/20200-23-21-21N/A
3/31/20202-19-21-21N/A
12/31/20192-22-21-21N/A
9/30/20192-21-21-21N/A
6/30/20192-22-24-24N/A
3/31/20191-23-24-24N/A
12/31/20181-21-23-23N/A
9/30/20181-21-22-22N/A
6/30/20181-23-22-22N/A
3/31/20181-21N/A-23N/A
12/31/20171-24N/A-24N/A
9/30/20171-23N/A-24N/A
6/30/20172-18N/A-19N/A
3/31/20174-21N/A-17N/A
12/31/20166-20N/A-16N/A
9/30/201615-11N/A-16N/A
6/30/201615-15N/A-22N/A
3/31/201613-19N/A-26N/A
12/31/201511-24N/A-31N/A
9/30/20152-41N/A-40N/A
6/30/20150-50N/A-46N/A
3/31/20150-57N/A-51N/A
12/31/20141-64N/A-58N/A
9/30/20143-65N/A-61N/A
6/30/20144-71N/A-62N/A
3/31/20144-68N/A-64N/A
12/31/20135-65N/A-61N/A

애널리스트 미래 성장 예측

수입 대 저축률: Insufficient data to determine if 0T20's forecast earnings growth is above the savings rate (0.8%).

수익 vs 시장: Insufficient data to determine if 0T20's earnings are forecast to grow faster than the German market

고성장 수익: Insufficient data to determine if 0T20's earnings are expected to grow significantly over the next 3 years.

수익 대 시장: 0T20's revenue (1% per year) is forecast to grow slower than the German market (5.5% per year).

고성장 수익: 0T20's revenue (1% per year) is forecast to grow slower than 20% per year.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: Insufficient data to determine if 0T20's Return on Equity is forecast to be high in 3 years time


성장 기업 발견